Company Overview and News
2018-09-05 seekingalpha - 9
While much attention is being riveted on the S&P 500's new all-time high eclipsing the January one, small caps accomplished that in May.
VRTX ECYT VSTM TRXC VKTX ENL CVS LGNDZ RGNX IMMU BIIB LGNYZ REGI HRTX NVTA NBIX ARWR SRPT ICPT VKTXW XLRN FNKO MRTX LGNZZ LGND NVS HEAR LGNXZ NTRA UNH PFE ENDP
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](")[email protected]@,2GWPQ,C P'0+(,C.C$?\;)?P "# #[email protected]?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
2018-09-04 zacks - 2
Geron Corporation (GERN - Free Report) shares have risen 218.3% so far this year against the industry’s decline of 1.7% as it makes rapid progress on the development of its sole pipeline candidate, imetelstat.
XLRN CELGZ GERN JNJ CELG
2018-09-01 seekingalpha - 2
Discussion: Pfizer (PFE) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy (DMD). The decision followed a disappointing Phase 2 study (B5161002) primarily concerned with safety and efficacy of the data in which the candidate failed to achieve the primary endpoint. The study completed almost 2/3rd of the planned trial and without any major adverse reports could have continued till its completion within a year in August 2019.
SRRK AZN GSK RGNX SHPG AZN XLRN BIIB JNJ INSY GSK NVS ADVM PFE ALNY
2018-08-15 zacks - 9
On Aug 14, we issued an updated research report on Geron Corporation (GERN - Free Report) . This developmental stage biopharmaceutical company, based in Cambridge, MA, is focused on the development of first-in-class therapeutic products with its patented core technology, telomerase, for the treatment of cancer.
XLRN CELGZ GERN JNJ CELG
BOSTON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced changes to the Company’s Board of Directors. Scott Tarriff, a member of the Board since 2015, has been elected to serve as Lead Director, succeeding Sir Murray Brennan, M.D. Both Sir Dr. Brennan and former U.S. Sen. William Wyche Fowler will step down when their terms expire on September 18, 2018, the date of the annual meeting of shareholders.
ZIOP MKGAF EGRX XLRN XON MKGAY BIIB AVEO PRTK
Good afternoon, ladies and gentlemen, and welcome to Acceleron Second Quarter 2018 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference may be recorded.
Acceleron Pharma (XLRN - Free Report) just came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.77 per share a year ago. These figures are adjusted for non-recurring items.
Document Table of Contents UNITED STATES
2018-07-27 zacks - 4
Celgene Corporation (CELG - Free Report) reported better-than-expected results for the second quarter of 2018. The results come as a breather for investors who bore the brunt of the decline in share price, due to series of setbacks over the last few months.
XLRN EQT CELGZ BLUE CELG BLUE
Celgene announced data from its Phase III AUGMENT clinical trial that compared Revlimid (lenalidomide) and rituximab to placebo in relapsed/refractory follicular and marginal zone lymphoma. There was a highly statistically significant improvement in the primary endpoint of progression-free survival (PFS).
XLRN CELGZ CELG
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET